Consort Partners

"I'm just really happy when I see that people who had struggled to get a doctor's visit, struggle to understand what's going on can get a clear picture of their disease and then take some action around that..." Brian Pepin, CEO and Founder of Rune Labs, was interviewed by KTVU 2 FOX in San Francisco yesterday afternoon to discuss the National Plan to End Parkinson's Act signed into law by President Biden, the impact of federal research funding and the Parkinson's task force, plus the efforts of #StrivePD to improve patients' quality of care. Watch the interview below:

In a column for MedCity News, Freespira CEO Joseph Perekupka addresses the tendency to prioritize novel therapies like MDMA-assisted treatment for PTSD over proven, readily available treatments. Perekupka also highlights the risks of neglecting effective treatments due to lengthy approval processes and challenges associated with new drugs. He advocates for balancing enthusiasm for future innovations with the use of existing solutions to provide immediate relief to those currently suffering. #MentalHealth #PTSD #MDMA #PTSDSupport #Healthcare https://lnkd.in/gMFPvU9N

In a conversation with Luisa Torres, PhD of Drug Discovery News, Kyverna Therapeutics Chief Medical Officer James Chung discusses the potential of CAR T-cell therapy for multiple sclerosis, gives an update on #KYV101’s clinical progress, and expresses his enthusiasm for the future of autoimmune disease research at Kyverna. Chung also shares how there is an opportunity to use CAR T cells to test the hypothesis about B cell depletion in a more complete way and to see if there could be unprecedented levels of efficacy. #CARTcelltherapy #AutoimmuneDisease #MultipleSclerosis https://lnkd.in/eqTBG8Yw

Soda Health and Albertsons have collaborated on an expanded service to make it even easier for Medicare Advantage members to use their supplemental benefits, as Progressive Grocer's Bridget Goldschmidt reports. Soda Health is the first—and currently the only—benefits card accepted by the food retailer’s online portal for ordering and delivery. #healthcaretech #healthcare #medicare https://lnkd.in/ee7-Earn

Faeth Therapeutics CEO and Co-Founder Anand Parikh says the potential of Artificial Intelligence to accelerate medical discovery is immense, particularly within biology. Embracing AI in biology means tackling some of the most complex and variable aspects of science for the very first time. By focusing AI’s power on the untapped potential of the metabolic genome in cancer research, for example, we are not just making incremental improvements but are positioned to make quantum leaps in understanding, managing and treating cancer. By doing so, we are setting the stage for discoveries that could fundamentally alter our approach to health and disease, making biology the next great frontier for AI. Read Anand's full thoughts in Drug Discovery & Development: https://lnkd.in/gA3A9sgS

Rune Labs is excited to celebrate the signing of the National Plan to End Parkinson’s Disease into law. This groundbreaking legislation unites federal and philanthropic efforts to enhance diagnosis and treatment, ensuring essential care for American families. Our CEO, Brian Pepin, highlights this milestone: "The National Plan to End Parkinson's Disease aligns perfectly with our mission at Rune Labs. We look forward to leveraging our StrivePD platform in partnership with the National Parkinson’s Project to make a real difference for the Parkinson’s community." With our StrivePD platform, we’re revolutionizing Parkinson’s care through continuous, real-time symptom tracking via the Apple Watch, combined with AI-derived insights to optimize treatment. Parkinson’s advocate, Benjamin Stecher, adds, "This plan brings new hope for the Parkinson's community. Together, through collaboration and innovation, we can significantly improve care." We’re eager to collaborate with the Department of Health and Human Services and other stakeholders to achieve the goals of this national plan. https://lnkd.in/ex56tZAe #ParkinsonsDisease #PrecisionMedicine #HealthcareInnovation #StrivePD #RuneLabs #EndParkinsons #PrecisionNeurology 

In an interview with Daily Mail's Cassidy Morrison, Chief Medical Officer James Chung of Kyverna Therapeutics offers an insightful look into the challenges faced by individuals with #StiffPersonSyndrome, as Celine Dion bravely opens up about her own battle with this rare condition. Chung discusses what patients feel during acute spasms and how this autoimmune attack leads to muscles not having proper control over how they contract and relax. #AutoimmuneDisease #CARTcelltherapy #HopeForSPS https://lnkd.in/e-XsM9Hz

As of yesterday afternoon, H.R. 2365, the “National Plan to End Parkinson’s Act,” is the law of the land in the United States: https://lnkd.in/g67JvF62 Greater than 70% of all dollars spent on Parkinson’s in the US flow directly from the federal government through Medicare and other agencies -> more than $20B annually.  Over time, this legislation will direct more of these dollars to two key priorities, both of which have historically been under-resourced: (A) early diagnosis of Parkinson’s -> alert patients to needed lifestyle changes and get them matched to clinical trials for disease modifying therapies.   (B) coordination of the care and treatment of individuals with Parkinson’s -> take a holistic view of a patient’s disease and needs (and data) to get them a personalized care plan that improves their short- and long-term outcomes I’m looking forward to using Rune Labs StrivePD precision medicine platform for Parkinson’s to make these goals a reality, and maximize the value of every federal $$$ spent for Parkinson’s patients and their caregivers 🧠 🇺🇲 🧠 Thanks Congressman Michael Bilirakis Congressman Paul Tonko Congresswoman Jennifer Wexton Senator Shelley Moore Capito Senator Laura Murphy and the work of all the Parkinson's patient advocates who made this happen!

Labiotech.eu's Roohi M. highlights Nucleus RadioPharma's closure of its Series A extension round with AstraZeneca last month. The funding expands the accessibility and impact of these life-saving treatments, paving the way for large-scale production and instilling optimism in those with limited options. #CDMO #funding #radiopharmaceuticals https://lnkd.in/g5ZwiV2T

Spatial AI biomarker company Nucleai has partnered with Proscia to enhance precision medicine biomarkers for clinical trials. As Drug Discovery World reports, Nucleai’s predictive biomarker solutions will be integrated into Proscia’s Concentriq software platform. #AI #precisionmedicine #clinicaltrials #spatialbiology https://lnkd.in/ebwpPs5A